Status:
TERMINATED
TALL-104 and Gleevec in Chronic Myelogenous Leukemia Patients
Lead Sponsor:
M.D. Anderson Cancer Center
Collaborating Sponsors:
Abiogen Pharma
Conditions:
Chronic Myelogenous Leukemia
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
Objectives: * To determine the response rate and duration of response with combination of TALL-104 cells and imatinib mesylate (IM) therapy in patients with chronic myelogenous leukemia in chronic ph...
Detailed Description
Imatinib mesylate is designed to block the enzyme that is believed to be responsible for starting the type of leukemia patient has. TALL-104 cells are cells of the immune system that have been obtaine...
Eligibility Criteria
Inclusion
- Patients with CML in chronic phase who have failed to achieve or have lost an adequate response to IM. For the purpose of this trial this will be defined as a lack of any cytogenetic response after 6 months of therapy or lack of major cytogenetic response after 12 months of therapy with IM. Patients that have lost their major or complete cytogenetic response will also be eligible. Patients who show a sustained increase in breakpoint cluster region gene (BCR)-Abelson gene (ABL)/ABL \[BCR-ABL/ABL\] ratio of \>/= 1-log confirmed in at least two consecutive Polymerase Chain Reaction (PCR) analyses (at least one month apart from each other) will also be eligible.
- \*continued from above: Patients with stable molecular response defined as 2 consecutive PCR-positive results (no more than 1/2 log improvement) will also be eligible. Patients must be taking stable dose of IM for at least 3 months before study enrollment, and recovered from all toxicities related to IM, to grade 0-1.
- Patients should be in complete or partial hematological remission, including white blood count (WBC) \</=20 x 10(9)/L, and platelets \</= 600 x 10(9)/L.
- Eastern Cooperative Oncology Group (ECOG) scale performance status of 2 or less.
- Age greater than 18 years of age since disease is extremely rare in younger age groups.
- Adequate liver (total bilirubin of less than 2 times and aspartate aminotransferase (AST) or alanine aminotransferase (ALT) of less than 2 times upper limits of normal), and renal function (creatinine of less than 2 times upper limit of normal).
- Signed informed consent form.
- Negative pregnancy test in women of childbearing age.
- Negative hepatitis B and C screening blood tests.
Exclusion
- Serious intercurrent medical illnesses or active infections requiring parenteral antibiotics that would interfere with the ability of the patient to carry out the treatment program.
- Female patients who are pregnant or breast-feeding.
- Patients taking steroids, or those anticipated to receive steroids during the trial therapy.
- Prior bone marrow transplant.
- Known positivity for human immunodeficiency virus (HIV).
Key Trial Info
Start Date :
December 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2013
Estimated Enrollment :
3 Patients enrolled
Trial Details
Trial ID
NCT00415909
Start Date
December 1 2006
End Date
May 1 2013
Last Update
June 30 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
UT MD Anderson Cancer Center
Houston, Texas, United States, 77030